Abstract
Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the synovium that can lead to severe joint damage if insufficiently treated. Central to the pathogenesis of RA is the proliferation of synovial fibroblasts (synovial 'pannus') in response to the production of autocrine, but also paracrine molecules produced by infiltrating mononuclear cells. Among these molecules, proinflammatory cytokines such as tumour necrosis factor (TNF)-␣, interleukin (IL)-1␤, IL-6 or IL-17 play an important role, and this observation led to the development of targeted therapies. In this context, TNF blocking agents are used routinely in RA patients who have failed first-line disease-modifying anti-rheumatic drugs (DMARD) therapy.
Several TNF blocking agents are presently available, which display similar effects in terms of efficacy, tolerability and side effects in RA [1] [2] [3] [4] [5] . Importantly In earlier experiments, we performed global gene expression studies on synovial biopsies obtained from RA patients prior to the initiation of TNF-blockade [6] . We found that several genes were significantly overexpressed at baseline in non-responders.
Strikingly, the expression of these genes is induced in vitro in fibroblast-like synovial cells (FLS) by the addition of TNF-␣, IL-1␤ and combinations of TNF-␣ and IL-1␤ or TNF-␣ and IL-17, thereby suggesting that these cytokines play a role in the mechanisms of primary resistance to TNF blockade in RA.
The interleukin-7 receptor ␣-chain (IL-7R) is one of the genes overexpressed in the synovial tissue of poor responders to TNF blockade in RA [6] . Fibroblasts are known to produce a soluble form of the molecule (sIL-7R), which results from an alternative splicing of the full-length transcript (excision of exon 6, containing the transmembrane domain) and is able to bind and block IL-7 [7, 8] . We therefore wondered whether sIL-7R expression was also regulated in synovial fibroblasts by the addition of pro-inflammatory cytokines and whether serum sIL-7R determination had any value in predicting primary response to TNF blockade in RA. (Fig. 1A) . (Fig. 1B) .
Materials and methods
Patients
RT-PCR experiments
Sequencing of the amplicons demonstrated that these isoforms correspond to the native IL-7R, and an alternatively spliced variant lacking exon 6 (transmembrane domain), which encodes a soluble form of the IL-7R (sIL-7R)
sIL-7R expression by FLS is induced by pro-inflammatory cytokines
Because sIL-7R transcripts result from an alternative splicing of IL-7R mRNAs, we wondered whether expression of both IL-7R isoforms is similarly regulated in FLS by the addition of proinflammatory cytokines known to play a role in the pathogenesis of RA. We found that mRNA levels of both the membrane-bound and soluble forms of IL-7R are up-regulated by the addition of TNF-␣, IL-1␤ and combinations of TNF-␣ and IL-1␤ or TNF-␣ and IL-17 (Fig. 2A). Flow cytometry experiments were, however, unable to detect any cell surface expression of the membranebound IL-7R on FLS under any of these conditions (Fig. 2B). By contrast, ELISA experiments performed on culture supernatants indicated that sIL-7R secretion is induced in FLS by TNF-␣, IL-1␤ and the combination of both cytokines (Fig. 2C). Interestingly, sIL-7R gene expression is negative in activated CD8 T and B cells but slightly positive in activated CD4 T cells (Fig. 1A). Taken together, these results indicate that sIL-7R is a marker of fibroblast and, to a lesser extent, CD4 T-cell activation.
IL-7 blockade inhibits FLS-induced CD4 T-cell proliferation
Because sIL-7R is known to display IL-7 binding and blocking properties, we investigated whether it could interfere with synovial CD4 T-cell proliferation. RA FLS are known to express major histocompatibility complex (MHC) class II molecules and stimulate the proliferation of autologous synovial CD4 T cells. We found that the addition of IL-7 stimulates the proliferation of synovial CD4 T cells cultured in the presence of autologous FLS. By contrast, addition of a sIL-7R-Fc fusion protein blocks the proliferation of these cells (Fig. 2D). These results suggest that sIL-7R production by activated synovial fibroblasts could play a role in a negative feedback loop resulting in a decreased proliferation of synovial CD4 T cells.
sIL-7R serum levels are higher in RA patients compared to controls 
Fig. 1 FLS and activated CD4 T cells produce two IL-7R ␣-chain isoforms. (A) IL-7R Western blots on protein extracts from FLS and PBMC, and IL-7R PCR on cDNA from duplicate TNF-␣ and IL-1␤ activated FLS (1), IL-2 and PHA activated CD4 T cells (2), antigen-activated CD8 T cell clones (3) and B-EBV cells (4). Arrows indicate the expected sizes of the membranebound IL-7R. (B) Sequencing of purified IL-7R PCR fragments indicates that FLS produce a full-length IL-7R ␣-chain and a truncated form of the IL-7R ␣-chain lacking exon 6 encoding the transmembrane domain, thereby resulting in a secreted form of the molecule. early and DMARD-resistant RA patients, baseline sIL-7R serum levels did not correlate with serum CRP values or with DAS28-CRP scores (data not shown).
Baseline sIL-7R serum levels predict response to therapy in RA Synovial overexpression of IL-7R is associated with poor response to TNF blockade in DMARD-resistant RA patients [6] . We therefore wondered whether baseline serum sIL-7R levels would have the same informative value about response to TNF blocking therapy in RA. Strikingly, in patients displaying active disease despite DMARD therapy and subsequently treated with TNF blockade, elevated baseline sIL-7R serum levels strongly predicted poor response to anti-TNF therapy (Fig. 4A, B and C) 
Discussion
In a first part of our work, we showed that soluble IL-7R ␣-chain (sIL-7R) gene expression is induced in FLS by the addition of pro-inflammatory cytokines (TNF-␣, IL-1␤ and combinations of TNF-␣ and IL-1␤ or TNF-␣ and IL-17
